TPO and differentiated thyroid carcinoma: We demonstrated the expected variability of the observed TPO cfRNA level peri-operatively and under thyroid stimulating hormone (TSH) stimulation for adjuvant RAI therapy in a patient (CBN049) with Stage I papillary thyroid carcinoma [T3N0M0] (Figure 4A).